Skip to main content

Table 2 Incidence of treatment-related grade ≥ 3 adverse events by patient characteristics in patients with PTCL a

From: Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma

 

No.

Infection

Thrombocytopenia

Neutropenia

Anemia

Asthenic conditions

Nausea and vomiting

PTCL subtypes

  PTCL NOS

69

4

20

17

4

7

4

  AITL

27

4

30

22

7

4

0

  ALK-1–negative ALCL

21

5

24

14

0

5

5

  Other

14

21

31

36

14

0

7

Age

  < 65 years

86

6

23

22

6

4

6

  ≥ 65 years

45

7

22

16

4

9

0

International Prognostic Index score

  0-1

31

3

19

13

10

0

7

  ≥ 2

100

7

24

22

4

7

3

Prior systemic therapies

  < 3

83

6

15b

21

8

5

5

  ≥ 3

48

6

38b

19

0

6

2

Prior stem cell transplant

  Yes

21

0

33

10

5

5

0

  No

110

7

21

22

6

6

5

Prior monoclonal antibody therapyc

  Yes

20

20d

35

50e

5

5

0

  No

111

4d

21

14e

5

5

5

Bone marrow involvement

  Yes

37

8

30

24

5

5

0

  No

94

5

20

18

5

5

5

  1. AITL, angioimmunoblastic T-cell lymphoma; ALCL, anaplastic large cell lymphoma; ALK, anaplastic lymphoma kinase; PTCL NOS, peripheral T-cell lymphoma not otherwise specified.
  2. aAll comparisons except those noted below were not significant (P > .05).
  3. bPrimarily rituximab or alemtuzumab.
  4. c P = .005.
  5. d P = .019.
  6. e P < .001.